- Home
- OXM vs CAPR Comparison
OXM vs CAPR Comparison
Compare OXM & CAPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OXM
- CAPR
- Stock Information
- Founded
- OXM 1942
- CAPR 2005
- Country
- OXM United States
- CAPR United States
- Employees
- OXM N/A
- CAPR N/A
- Industry
- OXM Apparel
- CAPR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- OXM Consumer Discretionary
- CAPR Health Care
- Exchange
- OXM Nasdaq
- CAPR Nasdaq
- Market Cap
- OXM 672.2M
- CAPR 600.7M
- IPO Year
- OXM N/A
- CAPR N/A
- Fundamental
- Price
- OXM $41.17
- CAPR $8.26
- Analyst Decision
- OXM Hold
- CAPR Strong Buy
- Analyst Count
- OXM 6
- CAPR 7
- Target Price
- OXM $55.80
- CAPR $40.14
- AVG Volume (30 Days)
- OXM 510.6K
- CAPR 2.5M
- Earning Date
- OXM 06-11-2025
- CAPR 08-06-2025
- Dividend Yield
- OXM 6.69%
- CAPR N/A
- EPS Growth
- OXM 100.54
- CAPR N/A
- EPS
- OXM 5.14
- CAPR N/A
- Revenue
- OXM $1,511,278,000.00
- CAPR $17,363,588.00
- Revenue This Year
- OXM $0.49
- CAPR $258.96
- Revenue Next Year
- OXM $1.90
- CAPR $8.02
- P/E Ratio
- OXM $8.03
- CAPR N/A
- Revenue Growth
- OXM N/A
- CAPR N/A
- 52 Week Low
- OXM $38.74
- CAPR $3.52
- 52 Week High
- OXM $108.51
- CAPR $23.40
- Technical
- Relative Strength Index (RSI)
- OXM 30.89
- CAPR 36.50
- Support Level
- OXM $40.46
- CAPR $11.57
- Resistance Level
- OXM $43.00
- CAPR $13.51
- Average True Range (ATR)
- OXM 2.58
- CAPR 1.70
- MACD
- OXM -1.40
- CAPR -0.33
- Stochastic Oscillator
- OXM 13.77
- CAPR 24.52
About OXM Oxford Industries Inc.
Oxford Industries Inc is an apparel manufacturing company that designs, sources, markets, and distributes products under the brand name Tommy Bahama, and Lilly Pulitzer. Tommy Bahama designs, sources, markets, and distributes men's and women's sportswear and related products. Lilly Pulitzer designs, sources, markets, and distributes upscale collections of women's and women's dresses, sportswear, and related products. The company generates majority of its revenue from the Tommy Bahama division.
About CAPR Capricor Therapeutics Inc.
Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.